WO2017143964A1 - Quisinostat，一种新型的高效抗疟药物 - Google Patents

Quisinostat，一种新型的高效抗疟药物 Download PDF

Info

Publication number
WO2017143964A1
WO2017143964A1 PCT/CN2017/074255 CN2017074255W WO2017143964A1 WO 2017143964 A1 WO2017143964 A1 WO 2017143964A1 CN 2017074255 W CN2017074255 W CN 2017074255W WO 2017143964 A1 WO2017143964 A1 WO 2017143964A1
Authority
WO
WIPO (PCT)
Prior art keywords
acid
plasmodium
pharmaceutically acceptable
composition
quisinostat
Prior art date
Application number
PCT/CN2017/074255
Other languages
English (en)
French (fr)
Inventor
江陆斌
黄正辉
Original Assignee
中国科学院上海巴斯德研究所
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 中国科学院上海巴斯德研究所 filed Critical 中国科学院上海巴斯德研究所
Publication of WO2017143964A1 publication Critical patent/WO2017143964A1/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the invention belongs to the field of medicine, and in particular to a novel high-efficiency antimalarial drug.
  • Malaria is an infectious febrile disease caused by Plasmodium protozoa, which is parasitic in red blood cells and spread by the bite of infected mosquitoes of the genus Anophele.
  • the disease is characterized by the onset of chills, fever and night sweats that occur at intervals that depend on the time required for a new generation of parasites to develop in vivo. After recovery from an acute attack, the disease tends to become chronic with occasional recurrence.
  • Plasmodium Plasmodium falciparum/P.falciparum
  • Plasmodium vivax/P.vivax Plasmodium malariae/P.malariae
  • Plasmodium. Ovale/P.ovale There are four Plasmodium, Plasmodium falciparum/P.falciparum, Plasmodium vivax/P.vivax, Plasmodium malariae/P.malariae, and Plasmodium. Ovale/P.ovale).
  • Plasmodium falciparum is characterized by severe systemic symptoms and sometimes death, which is the cause of most cases of human mortality. Plasmodium falciparum is dangerous not only because it digests the hemoglobin of red blood cells, but also because it alters the adhesion characteristics of the cells inhabited, which causes the cells to stick to the walls of blood vessels. This becomes dangerous when infected blood cells stick to blood vessels and block blood flow.
  • the disease is prevalent in tropical and subtropical regions of the world, including the Amazon region of Brazil, eastern and southern Africa, and Southeast Asia. According to the World Health Organization's 2011 World Malaria Report, there were 216 million cases of malaria in 2010, and 81% of them were in the WHO Africa region. There were an estimated 655,000 malaria-related deaths in 2010, 86% of whom were children under the age of five.
  • an anti-plasmin composition comprising Quisinostat, an analog thereof, or a pharmaceutically acceptable salt thereof.
  • the composition includes a first active ingredient and a second active ingredient
  • the first active ingredient is Quisinostat, an analog thereof, or a pharmaceutically acceptable salt thereof;
  • the second active ingredient is piperaquine, an analog thereof, or a pharmaceutically acceptable salt thereof, and/or
  • Benzophenone an analog thereof, or a pharmaceutically acceptable salt thereof.
  • the Plasmodium is selected from the group consisting of Plasmodium falciparum, Plasmodium vivax, Plasmodium vivax, and Plasmodium ovale.
  • the piperaquine is piperaquine phosphate.
  • the molar ratio of the first active ingredient to the second active ingredient is from about 1 to 20:20 to 1, preferably from 1 to 10:10 to 1, more preferably from 1 to 5. : 5 to 1.
  • composition further comprises a pharmaceutically acceptable carrier or excipient.
  • the pharmaceutical composition is in the form of a tablet, granule, capsule, pill, injection, or oral solution.
  • the composition is a unit dosage form, and the content of the first active ingredient and the second active ingredient in each unit dosage form is about 0.1 to 1 (or 0.25-1) of the daily dose. Or 0.5-1), wherein the daily dose is 20-100 mg.
  • the daily dose is 25-70 mg, such as 25 mg, 40 mg, 50 mg.
  • a method of preventing and/or treating malaria comprising the steps of:
  • the subject comprises a human and a non-human mammal (e.g., a rodent).
  • a non-human mammal e.g., a rodent
  • the administration is carried out in an amount of from 1 to 1000 mg/kg body weight, preferably from 15 to 700 mg/kg body weight, more preferably from 20 to 500 mg/kg body weight, based on the weight of the first active ingredient. meter.
  • the disease is malaria.
  • Figure 1 shows the growth inhibitory effect of No. 37 compound on Plasmodium in vitro (EC 503.91 nM), artemisinin as a positive control (EC50 6.38 nM); the method of 3-day SYBR GREEN I cell growth assay was used to determine malaria The growth of protozoa.
  • Figure 2 shows the cytotoxic effect of the No. 37 compound on the human hepatoma cell line HepG2 and the human renal epithelial cell line 293T; and the selection index between the inhibitory effect of the No. 37 compound on Plasmodium and the toxicity to different cell lines, Artemisinin was used as a positive control; cell growth was measured by 3-day cell titer Glo, and 3-day SYBR GREEN I was used to determine the growth of Plasmodium.
  • Figure 3 shows the drug interaction between No.37 compound and common antimalarial drugs, sterol, artemisinin and piperaquine phosphate; drug interaction was carried out in vitro cultured Plasmodium using 3-day SYBR The method of GREEN I measures the growth of Plasmodium; FIC is the index of drug interaction.
  • Figure 4 shows the insecticidal effect of the No. 37 compound in mice; the No. 37 compound tested two different concentrations of 10 mg/kg and 20 mg/kg, and the combined concentrations were: No. 37 compound (10 mg/ Kg) + sterol (10 mg/kg); No. 37 compound (10 mg/kg) + piperaquine phosphate (10 mg/kg), artemisinin at 10 mg/kg and 30 mg/kg as positive control, DMSO as negative control .
  • Figure 5 shows that the inventors previously configured a solution of each compound at a concentration of 400 nM, and added 100 ul of complete medium to the B1-H12 wells in a 96-well plate, and added different volumes in a 200 ul system of A1-A12 wells. Two compound solutions that interact.
  • Figure 6 shows the analysis of the insecticidal efficiency of compounds against sexual Plasmodium.
  • Figure 7 shows the in vitro insecticidal efficiency of compounds against Plasmodium falciparum in vitro.
  • Quisinostat i.e., the compound No. 37 in the present invention
  • Quisinostat and Piperaquine and Lumefantrine were administered intravenously to mice, showing a remarkable synergistic effect, and also showed better insecticidal effect than artemisinin.
  • the present invention has been completed.
  • the Quisinostat and No. 37 compounds are the same compound.
  • the No. 37 compound which is an active ingredient of the present invention is a novel second-generation Hdac inhibitor which mainly acts on Hdac1 in the Hdac family Class I.
  • the chemical name of the No. 37 compound is: N-hydroxy-2-[4- ⁇ [(1-methyl ⁇ 1-3-ylmethyl)amino]methyl ⁇ -1-piperidinyl]-5- Pyrimidinecarboxamide
  • the structure of the No. 37 compound is as follows:
  • Analogs of the No. 37 compound include, but are not limited to, a compound formed by substituting one or more hydrogens and/or a hydroxyl group in the above structural formula, preferably the substituent is selected from the group consisting of halogen (F, Cl, br, I), C 1-8 alkyl, C 2-8 alkenyl, C 2-8 alkynyl, C 3-8 cycloalkyl, 3- to 12-membered heterocyclyl group, aryl group, heteroaryl group , CN, NO 2 .
  • halogen F, Cl, br, I
  • C 1-8 alkyl C 2-8 alkenyl, C 2-8 alkynyl, C 3-8 cycloalkyl, 3- to 12-membered heterocyclyl group, aryl group, heteroaryl group , CN, NO 2 .
  • a pharmaceutically acceptable salt refers to a salt that is suitable for contact with the tissue of a subject (eg, a human) without causing side effects of discomfort.
  • a pharmaceutically acceptable salt refers to a salt of a compound of No. 37 or an analog thereof with a pharmaceutically acceptable inorganic acid and an organic acid, wherein preferred inorganic acids include, but are not limited to, hydrochloric acid.
  • organic acids include, but are not limited to: formic acid, acetic acid, propionic acid, succinic acid, naphthalene disulfonic acid (1,5), asiamic acid, oxalic acid, tartaric acid , lactic acid, salicylic acid, benzoic acid, valeric acid, diethyl acetic acid, malonic acid, succinic acid, fumaric acid, pimelic acid, adipic acid, maleic acid, malic acid, sulfamic acid, styrene Acid, gluconic acid, ascorbic acid, nicotinic acid, isonicotinic acid, methanesulfonic acid, p-toluenesulfonic acid, citric acid, and amino acids.
  • the pharmaceutically acceptable salt of the compound of claim No. 37 of the present invention comprises a salt (for example, a potassium salt, a sodium salt, a magnesium salt, a calcium salt) of a compound of the present invention having an acidic group or has a base.
  • Salts of the compounds of the invention e.g., sulfates, hydrochlorides, phosphates, nitrates, carbonates).
  • mice were inoculated with a mouse malaria-killing strain Pb AnKa, and after 24 hours of inoculation, mice were subjected to artemisinin, No. 37 compound, and No. 37 compound + Piperaquine, No. 37 compound + Lumefantrine.
  • Different concentrations of intravenous administration are:
  • the structure is as follows:
  • Analogs of piperaquine include, but are not limited to, one or more hydrogens of the above formula, and/or one or more compounds formed by substitution of Cl, preferably the substituents are selected from the group consisting of halogens (F, Cl, Br, I), C 1-8 alkyl, C 2-8 alkenyl, C 2-8 alkynyl, C 3-8 cycloalkyl, 3- to 12-membered heterocyclic, aryl, hetero Aryl, CN, NO 2 .
  • halogens F, Cl, Br, I
  • a pharmaceutically acceptable salt refers to a salt that is suitable for contact with the tissue of a subject (eg, a human) without causing side effects of discomfort.
  • a pharmaceutically acceptable salt refers to a salt of piperaquine or an analogue thereof with a pharmaceutically acceptable inorganic and organic acid, wherein preferred inorganic acids include, but are not limited to, hydrochloric acid, hydrogen Bromic acid, phosphoric acid, nitric acid, sulfuric acid; preferred organic acids include, but are not limited to: formic acid, acetic acid, propionic acid, succinic acid, naphthalene disulfonic acid (1, 5), asiamic acid, oxalic acid, tartaric acid, lactic acid , salicylic acid, benzoic acid, valeric acid, diethyl acetic acid, malonic acid, succinic acid, fumaric acid, pimelic acid, Diacid, maleic acid, malic acid, sulfamic acid
  • the pharmaceutically acceptable salts of piperaquine or analogs thereof of the invention include salts (eg, potassium, sodium, magnesium, calcium) of a compound of the invention having an acidic group or Salts of the compounds of the invention having a basic group (e.g., sulfates, hydrochlorides, phosphates, nitrates, carbonates).
  • salts e.g., potassium, sodium, magnesium, calcium
  • Salts of the compounds of the invention having a basic group e.g., sulfates, hydrochlorides, phosphates, nitrates, carbonates.
  • Piperaquine phosphate was synthesized in the 1960s and was widely used in malaria prevention and treatment in China and India for the next 20 years. Until the 1980s, there was a resistant strain of piperaquine phosphate; due to its long half-life, it is now mostly used. Prevention and treatment of malaria with a combination of artemisinin (ACT).
  • ACT artemisinin
  • Lumefantrine an analog thereof, or a pharmaceutically acceptable salt thereof
  • the structure is as follows:
  • Analogs of phenyl sterol include, but are not limited to, compounds formed by substitution of one or more hydrogen, chlorine and/or hydroxyl groups in the above structural formula, preferably the substituents are selected from the group consisting of halogens (F, Cl, Br, I), C 1-8 alkyl, C 2-8 alkenyl, C 2-8 alkynyl, C 3-8 cycloalkyl, 3- to 12-membered heterocyclic, aryl, heteroaryl , CN, NO 2 .
  • halogens F, Cl, Br, I
  • a pharmaceutically acceptable salt refers to a salt that is suitable for contact with the tissue of a subject (eg, a human) without causing side effects of discomfort.
  • a pharmaceutically acceptable salt refers to a salt of phenylhydrin or an analogue thereof with a pharmaceutically acceptable inorganic and organic acid, wherein preferred inorganic acids include, but are not limited to, hydrochloric acid, Hydrobromic acid, phosphoric acid, nitric acid, sulfuric acid; preferred organic acids include, but are not limited to: formic acid, acetic acid, propionic acid, succinic acid, naphthalene disulfonic acid (1, 5), asiamic acid, oxalic acid, tartaric acid, Lactic acid, salicylic acid, benzoic acid, valeric acid, diethyl acetic acid, malonic acid, succinic acid, fumaric acid, pimelic acid, adipic acid, maleic acid, malic acid, sulf
  • the present invention A pharmaceutically acceptable salt of a phenyl sterol or an analogue thereof, which comprises a salt of a compound of the invention having an acidic group (for example, a potassium salt, a sodium salt, a magnesium salt, a calcium salt) or a basic group Salts of the compounds of the invention (e.g., sulfates, hydrochlorides, phosphates, nitrates, carbonates).
  • an acidic group for example, a potassium salt, a sodium salt, a magnesium salt, a calcium salt
  • Salts of the compounds of the invention e.g., sulfates, hydrochlorides, phosphates, nitrates, carbonates.
  • This sterol has a long half-life, and its main use is now with the combination of artemisinin (ACT) for the prevention and treatment of malaria.
  • ACT artemisinin
  • composition includes pharmaceutical compositions and agents.
  • compositions of the present invention comprise an active ingredient against Plasmodium, and a pharmaceutically acceptable carrier.
  • the active ingredient of the anti-Plasmodium includes a first active ingredient and a second active ingredient, wherein the first active ingredient comprises Quisinostat, an analog thereof, or a pharmaceutically acceptable salt thereof; and the second active ingredient is piperaquine phosphate, An analog thereof, or a pharmaceutically acceptable salt thereof, and/or
  • Benzophenone an analog thereof, or a pharmaceutically acceptable salt thereof.
  • the pharmaceutical composition of the present invention may further comprise various pharmaceutical excipients compatible with the compound or composition contained therein, and is prepared into a dosage form which is advantageous for administration by a conventional method, such as, but not limited to, an aqueous solution injection, a powder injection, a pill, Powder, tablet, patch, suppository, emulsion, cream, gel, granule, capsule, aerosol, spray, powder, sustained release and controlled release.
  • a conventional method such as, but not limited to, an aqueous solution injection, a powder injection, a pill, Powder, tablet, patch, suppository, emulsion, cream, gel, granule, capsule, aerosol, spray, powder, sustained release and controlled release.
  • the pharmaceutical excipients may be conventionally used in various preparations such as, but not limited to, isotonic agents, buffers, flavoring agents, excipients, fillers, binders, disintegrators, lubricants, and the like.
  • excipients can effectively improve the compounds contained in the composition
  • the stability and solubility or the release rate and absorption rate of the compound are changed, thereby improving the metabolism of various compounds in the living body, thereby enhancing the administration effect of the composition.
  • excipients such as, but not limited to, gelatin, albumin, chitosan, etc., may be used for achieving specific purposes or modes of administration, such as sustained release administration, controlled release administration, and pulsed administration.
  • Polyether and polyester polymer materials such as, but not limited to, polyethylene glycol, polyurethane, polycarbonate and copolymers thereof.
  • the main manifestations of the administration are: but not limited to, improving the therapeutic effect, improving bioavailability, reducing toxic side effects, and improving patient compliance.
  • excipients In aqueous solution injections, excipients generally include isotonic agents and buffers, as well as the necessary emulsifiers (eg, Tweeen-80, Pluronic, and Poloxamer, etc.), solubilizers, and bacteriostats. In addition, it also includes other pharmaceutically acceptable excipients such as antioxidants, pH adjusters and analgesics.
  • Excipients for the preparation of oral liquid preparations generally include a solvent, as well as a necessary flavoring agent, bacteriostatic agent, Emulsifiers, colorants, etc.
  • Excipients for preparing tablets generally include fillers (eg, starch, powdered sugar, dextrin, lactose, compressible starch, microcrystalline cellulose, calcium sulfate, calcium hydrogen phosphate, mannitol, etc.), binders (eg: ethanol, starch slurry, sodium carboxymethylcellulose, hydroxypropylcellulose, methylcellulose, ethylcellulose, hydroxypropylmethylcellulose, gelatin solution, sucrose solution and aqueous solution of polyvinylpyrrolidone Or alcohol solution, etc.), disintegrants (such as: dry starch, sodium carboxymethyl starch, low-substituted hydroxypropyl cellulose, cross-linked polyvinylpyrrolidone and croscarmellose sodium) and lubricants (such as: Magnesium stearate, micronized silica gel, talc, hydrogenated vegetable oil, polyethylene glycol 4,000, polyethylene glycol 6,000, magnesium lauryl sul
  • Excipients used in the preparation of emulsions are generally water, oils (e.g., fatty acids), emulsifiers, and necessary preservatives and flavoring agents.
  • the excipients used to make the granules are similar to tablets, but the granulation process is different. If necessary, the prepared granules are mixed with a glidant and then filled into capsules to obtain a capsule.
  • the terms "subject,” “organism,” “animal,” or “patient” include humans, wild animals, and livestock (Livestock). Wild animals are animals that have not been artificially domesticated in their natural state. Livestock are animals that are artificially raised to provide a source of food, such as, but not limited to, dogs, cats, rats, rats, hamsters, pigs, rabbits, cows, buffalo, bulls, sheep, goats, geese, and chickens.
  • the "patient” or “organism” to which the treatment is administered preferentially selects a mammal, especially a human.
  • prevention refers to various means or measures for preventing the occurrence or development of a disease, including medical, physical or chemical means, to prevent and reduce various diseases before the disease is not recognized by clinical standards. The occurrence or development of symptoms.
  • treating refers to the prevention and suppression of the development or progression of a disease, which inhibits, inhibits, alleviates, ameliorates, slows, stops, delays or reverses the progression of the disease. / or various indicators of disease, disorder, or pathological state at the time of administration include alleviating or reducing symptoms or complications, or curing or eliminating a disease, disorder, or condition.
  • drug refers to a single compound, a composition formed by a plurality of compounds, or a composition or a formulation having a single compound as a main active ingredient, which can be used for preventing or treating a certain disease, and A composition or formulation that is composed of a plurality of compounds as active ingredients.
  • “Drug” should be understood to refer not only to the products approved and approved for production by the administrative agencies established by the laws of a country, but also to the inclusion of a single compound as an active ingredient in order to obtain approval and approval of production. Various forms of matter. "Formation” should be understood as by chemical synthesis, biotransformation or Purchase and other ways to obtain.
  • the administration route provided by the present invention as a pharmaceutical composition includes, but is not limited to, oral (Oral), nasal (Nasal), buccal, transdermal, pulmonary (pulmonal), vaginal ( Vaginal), Subcutaneous or Intravenous is administered to the organism.
  • 4.293T cell line purchased from ATCC.
  • HepG2 cell line purchased from ATCC.
  • Culture Plasmodium Plasmodium culture using RPMI (containing NaHCO 3, HEPES, Albumax I, Hypoxanthine, Genaotamicin) complete medium (Complete Medium), in an incubator at 37 °C (5% CO 2, 5% 0 2) to cultivate.
  • RPMI containing NaHCO 3, HEPES, Albumax I, Hypoxanthine, Genaotamicin
  • Mammalian cell culture The mammalian cell line 293T and HepG2 were cultured in a 37 ° C incubator (5% CO 2 ) using DMEM (containing 10% FBS, 1X P/S).
  • Plasmodium culture 1% ring parasitemia, 4% HCT
  • 100 ul of Plasmodium culture 1% ring parasitemia, 4% HCT
  • the final concentration gradient of the compound was (200 nm, 100 nm, 50 nm, 25 nm).
  • C incubator 5% CO 2, 5% O2
  • Compound cytotoxicity IC50 determination mammalian cells 293T, HepG2 were cultured to p5 generation, digested with trypsin-EDTA, resuspended in DMEM (10% FBS, 1X p/S), counted and diluted to 10 with a hemocytometer. 5 cell/ml. 100ul of cell suspension was added to each well of a 96-well plate by robot hand, and cultured at 37 ° C, 5% CO 2 for 24 h. Add 100 ul of DMEM (10% FBS, No p/s) to each well of a new 96-well plate, and add 200 ⁇ l of 1 uM compound (dissolved in DMEM) to the first well of a 96-well plate.
  • Determination of interactions with commonly used antimalarials Select an optimal starting concentration based on the single EC50 of the compound and antimalarial drug to ensure that the EC50 concentration value is optimal in the middle of the concentration gradient.
  • the compound is commonly used.
  • the initial concentration of the antimalarial drug was set at 200 nM. Therefore, the inventors previously configured each compound solution at a concentration of 400 nM, and added 100 ul of complete medium to the B1-H12 well in a 96-well plate at A1-A12. In the 200 ul system of the wells, two compound solutions of different volume interactions were added, as shown in FIG.
  • mice Two different strains of mice were selected (ICR and BALB/c for this experiment, respectively, on day 0, all mice were vaccinated with the murine malaria-killing strain Pb ANKA, each The mice were inoculated with 10 6 Plasmodium, and after 24 hours, the mice were administered intravenously with different concentrations of artemisinin, No. 37, No. 37+piperaqiuoine, No. 37+lumefantrine, respectively, respectively, artemisinin 10 mg. /kg, 30 mg/kg; No. 3710 mg/kg, 20 mg/kg; No. 37+piperaquine (10 mg+10 mg)/kg; No.
  • mice 37+lumefantrine (10 mg+10 mg)/kg, three mice per group
  • the DMSO was used as a negative control at the same time.
  • the administration was continued for four days in the same manner, and all the mice were subjected to tail blood sampling every day to prepare a blood smear to calculate the protozoa rate in the mice, and the observation was continued for 10 days or more, and the results were plotted.
  • the inventors performed EC50 determination on No. 37 compound, using Artemsinin as a positive control, and performing a gradient dilution (11 gradients) at a ratio of 1/2 with a starting concentration of 200 nm according to the method described above. Incubation and calculation of inhibition rates, and finally using the Graph Pad to calculate the EC50 of compound inhibition against Plasmodium growth.
  • the results obtained by the present inventors are as shown in Fig. 1 and Compound No. 37 is equivalent to artemisinin, and exhibits a strong inhibitory effect on the growth of Plasmodium (P. falciparum (3D7C8)).
  • the present inventors performed human cytotoxicity assay using human renal epithelial cell line 293T and human hepatoma cell line HepG2, and compound 1um was used as a starting concentration and was diluted in a ratio of 1/2 (11 gradients), and artemisinin was used as a control. The methods described above were used for culture and inhibition rate calculations. Finally, use the Graph Pad for EC50 calculations. As shown ( Figure 2), Compound No. 37 showed very weak toxicity to cells, and its cytotoxic EC50 was about 1000-fold higher than EC50 against Plasmodium growth inhibition (Fig. 2).
  • mice In the mouse test, the inventors used two different strains of mice (BALB/c, ICR) to perform separate drug experiments, and each mouse was inoculated with 10 6 Plasmodium before administration, and was administered 24 hours later. The drug was administered continuously for 4 days, DMSO was used as a negative control, artemisinin was used as a positive control, and the change of the protozoa rate of the mouse was continuously recorded. As shown in Fig. 4, the inventors can see that the control group was protozoa soon after inoculation. The rate became very high, and the experimental group barely saw the malaria parasite, or the time of its occurrence was delayed a lot relative to the control group, and the inventors can see that the No. 37 compound group and the combination group thereof have an obvious effect. It is better than the control group of artemisinin.
  • the inventors used the NF54 geographic strain of Plasmodium to induce gametophyte in vitro, and then added the compound to the gametophyte in the system, 37 ° C incubator The medium was cultured for 24 hours, and then the culture system was mixed, and the gametophytic viability count was performed under a microscope using a cell counting plate. Solvent, chloroquine, chaetocin as a control, and No. 37 (2 nM) were used as an experimental group. As shown in Fig. 6, the control group had no significant inhibitory effect on Plasmodium falciparum, and chloroquine had almost no effect, while No.37 showed almost 100% inhibitory activity at half the concentration of EC50 in vitro. It is indicated that No.7 can inhibit the sexual production of Plasmodium, which will block the transmission of Plasmodium.
  • the inventors used the P. amalaria Pb Anka strain to produce sporozoites in the salivary gland of the mosquito through mosquito infection, and then took the mouse primary liver cells and extracted from the mosquitoes.
  • the sporozoites were used to infect the primary liver cells of mice, and different concentrations of No.37 compounds were added.
  • the cells were cultured for 3 days in a 37 °C incubator.
  • RNA was extracted from different groups of hepatocytes, and QPCR detection was performed using murine-specific primers. .
  • the ratio of sporozoites invading liver primary cells was obtained and plotted.
  • the inhibition of sporozoite invading hepatocytes by No. 37 was drug-dependent, and the sporozoite invasion was almost completely inhibited at a lower concentration, indicating that No. 37 can inhibit Plasmodium liver well. Period of infection.

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本发明提供了一种新型的高效抗疟药物，具体地本发明提供了Quisinostat、其类似物、或其药学上可接受盐在治疗疟疾中的应用。本发明还提供了含有Quisinostat的药物组合物。经过深入的研究发现Quisinostat对疟原虫具有显著的抑制效果，在小鼠体内甚至表现出了比青蒿素更好的杀虫效果。

Description

Quisinostat，一种新型的高效抗疟药物 技术领域
本发明属于医药领域，具体地说，本发明涉及一种新型的高效抗疟药物。
背景技术
疟疾是由疟原虫属原生动物造成的感染性发热性疾病，所述疟原虫属原生动物寄生在红血细胞中，并且通过疟蚊(Anophele)属受感染蚊子的叮咬传播。所述疾病的特征在于以一定间隔时间发生的发冷、发热和盗汗的发作，所述间隔时间取决于新一代寄生虫在体内发育所需的时间。从急性发作恢复后，所述疾病倾向于变成慢性的，偶有复发。存在四种疟原虫，恶性疟原虫(Plasmodium falciparum/P.falciparum)、间日疟原虫(Plasmodium vivax/P.vivax)、三日疟原虫(Plasmodium malariae/P.malariae)和卵形疟原虫(Plasmodium ovale/P.ovale)。
在各种形式的人类疟疾中，由恶性疟原虫引起的疟疾的特征在于严重的全身症状，有时甚至导致死亡，它是造成人类死亡率中的大多数病例的原因。恶性疟原虫是危险的，不仅因为它消化红血细胞的血红蛋白，而且还因为它改变了所栖息细胞的粘附特性，这造成所述细胞粘到血管壁上。当受感染的血细胞粘到血管上从而阻塞血液流动时，这变得危险。所述疾病在世界上的热带和亚热带地区普遍存在，包括巴西的亚马逊地区、东部和南部非洲以及东南亚地区。根据世界卫生组织2011年世界疟疾报告，在2010年有216,000,000例疟疾，并且其中81％在WHO非洲区。在2010年估计有655,000例疟疾有关的死亡，其中86％的受害者是5岁以下的儿童。
在整个近代史中，已经用多种药物来治疗疟疾，包括药物的组合。然而，抗药性疟疾虫株的出现已成为疟疾治疗中的显著问题。WHO建议青蒿素(artemisinin)与其它种类的抗疟疾药组合(基于青蒿素的组合疗法(ACT))作为由恶性疟原虫引起的疟疾的一线治疗。2009年在柬埔寨-泰国边境证实出现并且在缅甸和越南的部分地区疑似出现抗青蒿素的恶性疟原虫，因此，本领域中急需新的高效抗疟药的出现，来遏制疟疾的传播。
发明内容
本发明的目的在于提供一种新型的高效抗疟药物。
在本发明的第一方面，提供了Quisinostat、其类似物、或其药学上可接受盐的用途，用于制备
(1)预防和/或治疗疟疾的药物；和/或
(2)抑制和/或杀灭疟原虫的试剂。
本发明的第二方面，提供了一种抗疟原虫组合物，所述组合物包括Quisinostat、其类似物、或其药学上可接受盐。
在另一优选例中，所述组合物包括第一活性成分和第二活性成分，
其中，所述第一活性成分为Quisinostat、其类似物、或其药学上可接受盐；
所述第二活性成分为哌喹、其类似物、或其药学上可接受盐，和/或
苯芴醇、其类似物、或其药学上可接受盐。
在另一优选例中，所述疟原虫选自下组：恶性疟原虫、间日疟原虫、三日疟原虫和卵形疟原虫。
在另一优选例中，所述哌喹为磷酸哌喹。
在另一优选例中，所述第一活性成分和第二活性成分的摩尔比约为1～20：20～1，优选地为1～10：10～1，更更优选地为1～5：5～1。
在另一优选例中，所述组合物中还包括药学上可接受的载体或赋形剂。
在另一优选例中，所述药物组合物的剂型包括片剂、颗粒剂、胶囊、丸剂、注射剂、或口服液。
在另一优选例中，所述的组合物为单元剂型，每个单元剂型中所述第一活性成分和所述第二活性成分的含量约为日剂量的0.1至1(或0.25-1，或0.5-1)，其中所述日剂量为20-100mg。
在另一优选例中，所述的日剂量为25-70mg，如25mg、40mg、50mg。
本发明的第三方面，提供了如本发明第一方面所述的抗疟原虫组合物的用途，用于制备
(1)预防和/或治疗疟疾的药物；
(2)抑制和/或杀灭疟原虫的试剂。
本发明的第四方面，提供了一种预防和/或治疗疟疾的方法，所述方法包括步骤：
给需要的对象施用Quisinostat、其类似物、或其药学上可接受盐，或者给需要的对象施用权利要求2所述的抗疟原虫组合物，从而预防和/或治疗疟疾。
在另一优选例中，所述的对象包括人和非人哺乳动物(如啮齿动物)。
在另一优选例中，所述的施用的用量为1-1000mg/kg体重，较佳地15-700mg/kg体重，更佳地20-500mg/kg体重，以所述第一活性成分的重量计。
在另一优选例中，所述疾病疟疾。
应理解，在本发明范围内中，本发明的上述各技术特征和在下文(如实施例)中具体描述的各技术特征之间都可以互相组合，从而构成新的或优选的技术方案。限于篇幅，在此不再一一累述。
附图说明
图1显示了No.37化合物对体外培养疟原虫的生长抑制效果(EC503.91nM)，青蒿素作为阳性对照(EC50 6.38nM)；采用3-day SYBR GREEN I细胞生长测定的方法来确定疟原虫的生长情况。
图2显示了No.37化合物对人肝癌细胞系HepG2以及人肾上皮细胞系293T的细胞毒性作用；同时显示了No.37化合物对疟原虫抑制效果与对不同细胞系毒性之间的选择指数，青蒿素作为阳性对照；采用3-day cell titer Glo的方法测定细胞系的生长情况，采用3-day SYBR GREEN I的方法来测定疟原虫的生长情况。
图3显示了No.37化合物与常用抗疟药，本芴醇、青蒿素、磷酸哌喹之间的药物互作情况；药物互作在体外培养的疟原虫中进行，采用3-day SYBR GREEN I的方法来测定疟原虫的生长情况；FIC为药物互作指数。
图4显示了No.37化合物在小鼠体内的杀虫效果；No.37化合物测试10mg/kg和20mg/kg这两个不同的浓度，同时联合用药浓度分别为:No.37化合物(10mg/kg)+本芴醇(10mg/kg)；No.37化合物(10mg/kg)+磷酸哌喹(10mg/kg)，青蒿素以10mg/kg和30mg/kg作为阳性对照，DMSO作为阴性对照。
图5显示了本发明人事先配置好浓度为400nM的各化合物溶液，在96孔板中的B1-H12孔中分别加入100ul完全培养基，在A1-A12孔的200ul体系中，分别加入不同体积相互作用的两种化合物溶液。
图6显示了化合物对有性期疟原虫杀虫效率分析。
图7显示了化合物对肝期疟原虫体外杀虫效率分析。
具体实施方式
本发明人通过广泛而深入的研究，意外地发现Quisinostat(即，本发明中的No.37化合物)对疟原虫具有显著的抑制效果，在小鼠体内甚至表现出了比青蒿素更好的杀虫效果。进一步地研究发现，发现Quisinostat与Piperaquine和Lumefantrine分别联合用药对小鼠进行静脉注射，表现出了显著的协同作用，同样表现出了比青蒿素更好的杀虫效果。在此基础上，完成了本发明。
在描述本发明之前，应当理解本发明不限于所述的具体方法和实验条件，因为这类方法和条件可以变动。还应当理解本文所用的术语其目的仅在于描述具体实施方案，并且不意图是限制性的，本发明的范围将仅由所附的权利要求书限制。
除非另外定义，否则本文中所用的全部技术与科学术语均具有如本发明所属领域的普通技术人员通常理解的相同含义。如本文所用，在提到具体列举的数值中使用时，术语“约”意指该值可以从列举的值变动不多于1％。例如，如本文所用，表述“约100”包括99和101和之间的全部值(例如，99.1、99.2、99.3、99.4等)。
虽然在本发明的实施或测试中可以使用与本发明中所述相似或等价的任何方法和材料，本文在此处例举优选的方法和材料。
Quisinostat、其类似物、或其药学上可接受盐
在本发明中，Quisinostat和No.37化合物为同一化合物。作为本发明活性成分的No.37化合物是新型的二代Hdac抑制剂，其主要作用于Hdac家族Class I中的Hdac1。No.37化合物的化学名称为：N-羟基-2-[4-{[(1-甲基吲哚1-3-基甲基)氨基]甲基}-1-哌啶基]-5-嘧啶羧酰胺
No.37化合物的结构如下：
Figure PCTCN2017074255-appb-000001
No.37化合物的类似物包括但不限于：上述结构式中的一个或多个氢、和/或羟基被取代后形成的化合物，优选地所述取代基选自下组：卤素(F、Cl、Br、I)、C1-8烷基、C2-8烯基、C2-8炔基、C3-8环烷基、3-至12-元杂环基，芳基、杂芳基、CN、NO2。
术语“药学上可接受的盐”指适合与对象(例如，人)的组织接触，而不会产生不适度的副作用的盐。如本文所用，药学上可接受的盐指No.37化合物或其类似物与药学上可接受的无机酸和有机酸所形成的盐，其中，优选的无机酸包括(但并不限于)：盐酸、氢溴酸、磷酸、硝酸、硫酸；优选的有机酸包括(但并不限于)：甲酸、乙酸、丙酸、丁二酸、萘二磺酸(1,5)、亚细亚酸、草酸、酒石酸、乳酸、水杨酸、苯甲酸、戊酸、二乙基乙酸、丙二酸、琥珀酸、富马酸、庚二酸、己二酸、马来酸、苹果酸、氨基磺酸、苯丙酸、葡糖酸、抗坏血酸、烟酸、异烟酸、甲磺酸、对甲苯磺酸、柠檬酸，以及氨基酸。在一些实施例中，本发明的No.37化合物的药学上可接受的盐包括具有酸性基团的本发明的化合物的盐(例如，钾盐，钠盐，镁盐，钙盐)或具有碱性基团的本发明的化合物的盐(例如，硫酸盐，盐酸盐，磷酸盐，硝酸盐，碳酸盐)。
在体外试验中No.37化合物表现出了与青蒿素相当的疟原虫生长抑制效果，而在小鼠试验中更表现出了比青蒿素更好的杀虫效果。在药物互作实验中，发现No.37与现在最主要的几类抗疟药没有相互拮抗作用，且在小鼠联合用药试验中，发现No.37与Piperaquine(磷酸哌喹)和Lumefantrine(苯芴醇)分别联合用药对小鼠进行静脉注射同样表现出了比青蒿素更好的杀虫效果。这意味着在未来成药研发以及临床试验中可以进行联合用药治疗，这对于延缓抗药性的产生将大有帮助，同时将会更好的更高效的进行疟疾治疗。
在体外疟原虫生长抑制实验中以青蒿素作为对照，No.37作为实验组对其疟原虫生长抑制EC50进行测定，No.37展现出了非常好的对疟原虫的生长抑制功能，与青蒿素相当，EC50为3.91nM。实验已进行三次以上生物学意义上的 重复，结果稳定，可信度高。
在小鼠实验中，对小鼠接种鼠疟致死株系Pb AnKa，并在接种24小时之后对小鼠进行青蒿素、No.37化合物以及No.37化合物+Piperaquine、No.37化合物+Lumefantrine不同浓度的静脉注射给药，分别为：
青蒿素10mg/kg,30mg/kg；
No.37 10mg/kg,20mg/kg；
No.37(10mg/kg)+Piperaquine(10mg/kg)；
No.37(10mg/kg)+Lumefantrine(10mg/kg)；
每组三只作为重复。同时注射DMSO作为阴性对照。实验结果显示No.37以及No.37+piperaquine、No.37+lumefantrine展现出了比青蒿素更好的对鼠疟的抑制效果，实验在不同种系的老鼠中做了多次重复，都得到了相似的结果，可信度高。
哌喹(Piperaquine)、其类似物、或其药学上可接受盐
化学名：1，3-双[4-(7-羟基喹啉-4-基)哌嗪-1基]丙烷
结构式如下：
Figure PCTCN2017074255-appb-000002
哌喹的类似物包括但不限于：上述结构式中的一个或多个氢、和/或一个或多个Cl被取代后形成的化合物，优选地所述取代基选自下组：卤素(F、Cl、Br、I)、C1-8烷基、C2-8烯基、C2-8炔基、C3-8环烷基、3-至12-元杂环基，芳基、杂芳基、CN、NO2。
术语“药学上可接受的盐”指适合与对象(例如，人)的组织接触，而不会产生不适度的副作用的盐。如本文所用，药学上可接受的盐指哌喹或其类似物与药学上可接受的无机酸和有机酸所形成的盐，其中，优选的无机酸包括(但并不限于)：盐酸、氢溴酸、磷酸、硝酸、硫酸；优选的有机酸包括(但并不限于)：甲酸、乙酸、丙酸、丁二酸、萘二磺酸(1,5)、亚细亚酸、草酸、酒石酸、乳酸、水杨酸、苯甲酸、戊酸、二乙基乙酸、丙二酸、琥珀酸、富马酸、庚二酸、己 二酸、马来酸、苹果酸、氨基磺酸、苯丙酸、葡糖酸、抗坏血酸、烟酸、异烟酸、甲磺酸、对甲苯磺酸、柠檬酸，以及氨基酸。在一些实施例中，本发明的哌喹或其类似物的药学上可接受的盐包括具有酸性基团的本发明的化合物的盐(例如，钾盐，钠盐，镁盐，钙盐)或具有碱性基团的本发明的化合物的盐(例如，硫酸盐，盐酸盐，磷酸盐，硝酸盐，碳酸盐)。
磷酸哌喹于20世纪60年代合成，之后的20年广泛用于中国和印度的疟疾预防和治疗，直到20世纪80年代出现了磷酸哌喹的耐药虫株；因其半衰期长，现在多用于与青蒿素的联合用药(ACT)进行疟疾的预防和治疗。
苯芴醇(Lumefantrine)、其类似物、或其药学上可接受盐
化学名：(Z)-2,7-二氯-9-[(4-氯苯基)亚甲基]-α-[(二正丁氨基)甲基]-9H-芴-4-甲醇
结构式如下：
Figure PCTCN2017074255-appb-000003
苯芴醇的类似物包括但不限于：上述结构式中的一个或多个氢、氯和/或羟基被取代后形成的化合物，优选地所述取代基选自下组：卤素(F、Cl、Br、I)、C1-8烷基、C2-8烯基、C2-8炔基、C3-8环烷基、3-至12-元杂环基，芳基、杂芳基、CN、NO2。
术语“药学上可接受的盐”指适合与对象(例如，人)的组织接触，而不会产生不适度的副作用的盐。如本文所用，药学上可接受的盐指苯芴醇或其类似物与药学上可接受的无机酸和有机酸所形成的盐，其中，优选的无机酸包括(但并不限于)：盐酸、氢溴酸、磷酸、硝酸、硫酸；优选的有机酸包括(但并不限于)：甲酸、乙酸、丙酸、丁二酸、萘二磺酸(1,5)、亚细亚酸、草酸、酒石酸、乳酸、水杨酸、苯甲酸、戊酸、二乙基乙酸、丙二酸、琥珀酸、富马酸、庚二酸、己二酸、马来酸、苹果酸、氨基磺酸、苯丙酸、葡糖酸、抗坏血酸、烟酸、异烟酸、甲磺酸、对甲苯磺酸、柠檬酸，以及氨基酸。在一些实施例中，本发 明的苯芴醇或其类似物的药学上可接受的盐包括具有酸性基团的本发明的化合物的盐(例如，钾盐，钠盐，镁盐，钙盐)或具有碱性基团的本发明的化合物的盐(例如，硫酸盐，盐酸盐，磷酸盐，硝酸盐，碳酸盐)。
本芴醇具有很长的半衰期，现在其最主要用途是和青蒿素的联合用药(ACT)进行疟疾的防治和治疗。
组合物
如本文所用，术语“组合物”包括药物组合物和试剂。
本发明所述的组合物包含抗疟原虫的活性成分，和药学上可接受的载体。抗疟原虫的活性成分包括第一活性成分和第二活性成分，其中，所述第一活性成分包括Quisinostat、其类似物、或其药学上可接受盐；而第二活性成分为磷酸哌喹、其类似物、或其药学上可接受盐，和/或
苯芴醇、其类似物、或其药学上可接受盐。
本发明的药物组合物还可以包含各种与所含化合物或组合物相适应的药物辅料，并通过常规方法制备成有利于给药的剂型，如：但不仅限于水溶液注射剂、粉针剂、丸剂、散剂、片剂、贴剂、栓剂、乳剂、霜剂、凝胶剂、颗粒剂、胶囊剂、气雾剂、喷雾剂、粉雾剂、缓释剂和控释剂等。所述药用辅料既可以是各种制剂中常规使用的，如：但不仅限于等渗剂、缓冲液、矫味剂、赋形剂、填充剂、粘合剂、崩解剂和润滑剂等；也可以是为了与所述物质相适应而选择使用的，如：但不仅限于乳化剂、增溶剂、抑菌剂、止痛剂和抗氧剂等，这类辅料能有效提高组合物所含化合物的稳定性和溶解性或改变化合物的释放速率和吸收速率等，从而改善各种化合物在生物体内的代谢，进而增强组合物的给药效果。此外，还可以为实现特定的给药目的或方式，如：缓释给药、控释给药和脉冲给药等，而使用的辅料，如：但不仅限于明胶、白蛋白、壳聚糖、聚醚和聚酯类高分子材料(如：但不仅限于，聚乙二醇、聚氨酯、聚碳酸酯及其共聚物等)。所述有利于给药的主要表现有：但不仅限于提高治疗效果、提高生物利用度、降低毒副作用和提高患者顺应性等。
在水溶液注射剂中，辅料一般包括等渗剂和缓冲液，以及必要的乳化剂(如：Tweeen-80、Pluronic和Poloxamer等)、增溶剂和抑菌剂等。此外，还包括含有药学上可接受的其它药用辅料，如：抗氧剂、pH调节剂和止痛剂等。
用于制取口服液体制剂的辅料一般包括溶剂，以及必要的矫味剂、抑菌剂、 乳化剂和着色剂等。
用于制取片剂的辅料一般包括填充剂(如：淀粉、糖粉、糊精、乳糖、可压性淀粉、微晶纤维素、硫酸钙、磷酸氢钙和甘露醇等)、粘合剂(如：乙醇、淀粉浆、羧甲基纤维素钠、羟丙基纤维素、甲基纤维素、乙基纤维素、羟丙基甲基纤维素、明胶溶液、蔗糖溶液和聚乙烯吡咯烷酮的水溶液或醇溶液等)、崩解剂(如：干淀粉、羧甲基淀粉钠、低取代羟丙基纤维素、交联聚乙烯吡咯烷酮和交联羧甲基纤维素钠)和润滑剂(如：硬脂酸镁、微粉硅胶、滑石粉、氢化植物油、聚乙二醇4,000、聚乙二醇6,000和月桂醇硫酸镁等)等。
用于制取乳剂的辅料一般为水、油(如：脂肪酸)、乳化剂，以及必要的防腐剂和矫味剂等。
用于制取颗粒剂的辅料与片剂类似，但造粒过程不同。根据需要，将制得的颗粒剂与助流剂混合后装入胶囊即得胶囊剂。
如本文所用，术语“对象”、“生物体”、“动物”或“患者”包括人、野生动物和家畜(Livestock)。野生动物为自然状态下未经人工驯化的动物。家畜是为了提供食物来源而人工饲养的动物，如：但不仅限于狗、猫、鼠、大鼠、仓鼠、猪、兔、奶牛、水牛、公牛、绵羊、山羊、鹅和鸡等。给予治疗的“患者”或“生物体”优先选择哺乳动物，尤其是人。
如本文所用，术语“预防”是指在未被临床标准认定的疾病前，各种用于防止疾病发生或发展的手段或措施，包括医学、物理或化学的方法，以阻止和降低疾病各种症状的发生或发展。
如本文所用，术语“治疗”是指为了阻止和降低疾病的发生或发展，使疾病病程的发展或加重得以抑制、遏制、减轻、改善、减缓、停止、延迟或反转，所描述的保持和/或用药时的疾病的、紊乱的或病理学状态的各种指标包括减轻或减少症状或并发症，或治愈或消除疾病、紊乱或状况。
如本文所用，术语“药物”是指可以用于预防或治疗某种疾病的单一化合物、多种化合物形成的组合物，或指以单一化合物为主要活性成分的组合物或制剂(formulation)，还指由多种化合物为活性成分的组合物或制剂。“药物”应理解为不仅指根据一国之法律规定，通过其设立的行政机构审批并准予生产的产品，还指在为了获得通过审批和准予生产的过程中，所形成的含单一化合物为活性成分的各类物质形态。“形成”应理解为通过化学合成、生物转化或 购买等途径获得。
本发明提供的作为药物组合物的给药途径，包括但不仅限于，口服(Oral)、鼻腔(Nasal)、(面)颊(Buccal)、透皮(Transdermal)、肺部(Pulmonal)、阴道(Vaginal)、皮下(Subcutaneous)或静脉(Intravenous)给予生物体。
本发明的主要优点在于：
(1)首次揭示了Quisinostat(即，本发明中的No.37化合物)对疟原虫具有显著的抑制效果；
(2)首次发现Quisinostat与Piperaquine和Lumefantrine分别联合用药表现出了对疟原虫的显著的协同抑制作用。
(3)提供了一类新的，效果显著的抗疟药物。
(4)提供了一种对疟药虫株更为有效的预防和治疗方案，同时该方案能有效的减缓疟原虫耐药性的出现。
下面结合具体实施例，进一步详陈本发明。应理解，这些实施例仅用于说明本发明而不用于限制本发明的范围。下列实施例中未注明详细条件的实验方法，通常按照常规条件如美国Sambrook.J等著《分子克隆实验室指南》(黄培堂等译，北京：科学出版社，2002年)中所述的条件，或按照制造厂商所建议的条件。除非另外说明，否则百分比和份数按重量计算。以下实施例中所用的实验材料和试剂如无特别说明均可从市售渠道获得。
材料和方法
一、材料
1.Artemisinin(青蒿素)Sigma Aldrich Cat.No.361593-100MG。
2.No.37化合物：Selleckchem Cat.No.S1096
3.恶性疟原虫(3D7C8)：购自ATCC。
4.293T细胞株:购自ATCC。
5.HepG2细胞株:购自ATCC。
6.SYBR Green I:Invitrogen Cat.No.S-7585
7.Cell titer Glo:Promega Cat.No.G7572
8.96-孔板:Corning
9.胰酶-EDTA:Gbico Cat.No.25200-072
10.DMEM:Gbico Cat.No.11965-092
11.FBS:Gbico Cat.No.10082-147
13.HEPES,ULTROL级(100g)CalBiochem Cat.No.391338
14.次黄嘌呤(Hypoxanthine，25g)SIGMA Cat.No.H9377
二、方法
1.疟原虫培养：疟原虫培养使用RPMI(含NaHCO3,HEPES,Albumax I,Hypoxanthine，Genaotamicin)完全培养基(Complete Medium)，在37℃培养箱(5％CO2，5％02)中培养。
2.哺乳动物细胞培养：哺乳动物细胞系293T和HepG2使用DMEM(含10％FBS，1X P/S)在37℃培养箱(5％CO2)中培养。
3.化合物疟原虫体外生长抑制EC50测定：100ul完全培养基加入到96孔板中，在第一孔中加入适量的1uM的化合物并用完全培养基定容至200ul使得化合物的终浓度为400nM，然后用机器手按1/2的比例进行梯度稀释(11个浓度梯度),Artemsinin作为正对照，不加任何化合物作为阴性对照，不加疟原虫和化合物作为实验背景。之后用机器手每孔加入100ul的疟原虫培养物(1％ring parasitemia，4％HCT)使得最终的HCT和parasitemia为2％和1％，化合物的终浓度梯度为(200nm、100nm、50nm、25nm、12.5nm、6.25nm、3.125nm、1.5625nm、0.78125nm、0.390625nm、0.195313nm)。加样完成之后96孔板放置到37℃培养箱(5％CO2,5％O2)中培养72h。培养完成之后每孔加入100ul Lysis Buffer(10x SYBR Green I,0.5％v/v Triton X-100,0.5mg/ml saponin，0.75％EDTA in Tris-Cl Buffer)，混匀之后，室温避光孵育2h。孵育完成之后用孔板荧光读数机读取数值(最大激发光/最大接受光：485nm/535nm)。根据荧光读值计算抑制率，抑制率＝(阴性对照组-实验组)/(阴性对照组-实验背景)，根据不同浓度的抑制率绘制生长抑制曲线并通过Graph Pad 6计算EC50。
4.化合物细胞毒性IC50测定：哺乳动物细胞293T、HepG2培养至p5代，采用胰酶-EDTA消化，用DMEM(10％FBS,1X p/S)重悬，用血球计算板计数并稀释至105cell/ml。用机器手在96孔板中每孔加入100ul细胞悬液，37℃、5％CO2培养24h。在新的96孔板中每孔加入100ulDMEM(10％FBS、No p/s)，在96孔板的第一孔中加入200ul 1uM的化合物(溶于DMEM)用机器手按1/2比例进 行梯度稀释(11个浓度梯度)，不加任何化合物作为阴性对照，只加DMEM作为背景。之后将先前96孔板中的培养液吸掉，再将梯度稀释之后的培养液对应加入到96-wellk孔板中。37℃5％CO2培养72h。培养完成之后取出96孔板在室温下平衡30min以上，之后每孔加入50ul cell title-Glo试剂(预先室温避光平衡1h以上)，室温摇晃孵育10分钟，之后用荧光检测仪器进行荧光检测。根据荧光读值计算抑制率，抑制率＝(阴性对照-实验组)/(阴性对照-背景)，根据不同药物浓度下的抑制率绘制生长抑制曲线并通过Graph Pad 6计算IC50。
与常用抗疟药相互作用测定：根据化合物和抗疟药的单一EC50选择一个最佳的起始浓度，以确保EC50的浓度值位于浓度梯度的中间为最佳，在本实验中，化合物与常用抗疟药的起始浓度值都定为200nM，因此本发明人事先配置好浓度为400nM的各化合物溶液，在96孔板中的B1-H12孔中分别加入100ul完全培养基，在A1-A12孔的200ul体系中，分别加入不同体积相互作用的两种化合物溶液，如图5所示。
之后从A-B按1/2比例进行梯度稀释，最后在每孔中加入100ulRBC压积为4％原虫率为1％的培养物使得最终的RBC压积为2％原虫率为1％，化合物的浓度梯度为(200nM，100，50，25，12.5，6.25，3.125，1.5625nM)，加样完成之后将96孔板放入三气培养箱中(5％CO2,5％O2)培养72h，培养完成之后每孔加入100ul Lysis Buffer(10x SYBR Green I,0.5％v/v Triton X-100,0.5mg/ml saponin，0.75％EDTA in Tris-Cl Buffer)，混匀之后，室温避光孵育2h。孵育完成之后用孔板荧光读数机读取数值(最大激发光/最大接受光：485nm/535nm)。根据荧光读值计算抑制率，抑制率＝(阴性对照组-实验组)/(阴性对照组-实验背景)，根据不同浓度的抑制率绘制不同组别生长抑制曲线并通过Graph Pad 6计算出每组的EC50。最后根据每组的EC50计算出两种化合物的相关系数，并绘制他们的相互作用关系图。
化合物在小鼠体内的杀虫效率分析：选择两种不同品系的小鼠(ICR和BALB/c分别进行此实验，第0天，对所有小鼠进行鼠疟致死株系Pb ANKA的接种，每只小鼠接种106个疟原虫，24小时之后对小鼠进行青蒿素、No.37以及No.37+piperaqiuoine、No.37+lumefantrine不同浓度的静脉注射给药，分别为青蒿素10mg/kg,30mg/kg；No.3710mg/kg,20mg/kg；No.37+piperaquine(10mg+10mg)/kg；No.37+lumefantrine( 10mg+10mg)/kg,每组三只小鼠作为重复。同时注射DMSO作为阴性对照。连续按相同的方式给药四天，每天对所有小鼠进行尾部采血制作血涂片计算小鼠体内原虫率，连续观察10天以上，并根据结果作图。
实施例1化合物疟原虫体外生长抑制EC50测定：
本发明人对No.37化合物进行EC50的测定，以青蒿素(Artemsinin)作为阳性对照，以200nm作为起始浓度按1/2的比例进行梯度稀释(11个梯度)按照上面描述的方法进行培养和对抑制率进行计算，最后使用Graph Pad计算化合物对疟原虫生长抑制的EC50。本发明人得到的结果如(图.1)，化合物No.37与青蒿素的效果相当，表现出了对疟原虫(恶性疟原虫(3D7C8))生长很强的抑制效果。
实施例2化合物细胞毒性EC50测定：
本发明人采用人肾上皮细胞293T和人肝癌细胞系HepG2进行细胞毒性实验测定，化合物1um作为起始浓度并按1/2的比例进行梯度稀释(11个梯度)，青蒿素作为对照，按上面所描述的方法进行培养和抑制率计算。最后使用Graph Pad进行EC50计算。如图所示(图2)，化合物No.37对细胞表现出很微弱的毒性，相比于对疟原虫生长抑制的EC50其细胞毒性EC50要高出约1000倍(图2)。
实施例3与常用抗疟药相互作用检测：
本发明人将No.37化合物与几种常用抗疟药，青蒿素(Artemisinin)，磷酸哌喹(Piperaqiuoine)，本芴醇(Lumefantrine)进行药物互作测试，实验结果如图3所示，No.37化合物与这三种常用抗疟药都未出现拮抗作用。
实施例4化合物在小鼠体内的杀虫效率分析：
在小鼠试验中，本发明人采用有两个不同品系的小鼠(BALB/c，ICR)来分别进行药物实验，给药前分别每只老鼠接种106的疟原虫，24小时之后进行给药,连续给药4天，DMSO作为负对照，青蒿素作为正对照，并连续记录小鼠原虫率的变化情况，如图4显示本发明人可以看到，对照组在接种之后很快原虫率就变得很高，而实验组则几乎看不到疟原虫，或者其出现的时间相对于对 照组推迟很多，而且本发明人可以看到No.37化合物组以及其联合用药组的效果明显要优于青蒿素的对照组。
实施例5化合物对有性期疟原虫杀虫效率分析：
在有性期杀虫效率(Sexual Commitment,％)分析实验中，本发明人采用疟原虫的NF54地理株系，通过体外诱导产生配子体，之后在配子体陪阿姨那个体系中加入化合物，37℃培养箱中培养24小时，之后混匀培养体系，利用细胞计数板在显微镜下进行配子体成活计数。溶剂(Solvent)、氯喹(chloroquine)、毛壳素(chaetocin)作为对照，No.37(2nM)作为实验组。如图6结果显示，对照组对有性期疟原虫的抑制效果不明显，氯喹几乎无效果，而No.37在一半体外EC50的浓度下却表现出了几乎100％的抑制活性。说明No.7能很好的抑制疟原虫有性期的生成，这将很好的阻断疟原虫的传播途径。
实施例6化合物对肝期疟原虫体外杀虫效率分析：
在肝期杀虫效率分析实验中，本发明人采用鼠疟Pb Anka虫株，通过蚊子感染在蚊子的唾液腺囊里面产生子孢子，之后取小鼠肝脏原代细胞，利用从蚊子中提取得到的子孢子去感染小鼠肝脏原代细胞，同时加入不同浓度的No.37化合物，37℃培养箱中连续培养3天，收集不同组的肝细胞提取RNA,用鼠疟特异性的引物进行QPCR检测。得到子孢子入侵肝脏原代细胞的比率，并作图。结果如图7显示，No.37对子孢子入侵肝细胞的抑制成药物依耐性，且在较低浓度下就能几乎完全抑制子孢子的入侵，说明No.37能很好的抑制疟原虫肝期的感染。
在本发明提及的所有文献都在本申请中引用作为参考，就如同每一篇文献被单独引用作为参考那样。此外应理解，在阅读了本发明的上述讲授内容之后，本领域技术人员可以对本发明作各种改动或修改，这些等价形式同样落于本申请所附权利要求书所限定的范围。

Claims (10)

  1. Quisinostat、其类似物、或其药学上可接受盐的用途，其特征在于，用于制备
    (1)预防和/或治疗疟疾的药物；和/或
    (2)抑制和/或杀灭疟原虫的试剂。
  2. 一种抗疟原虫组合物，其特征在于，所述组合物包括Quisinostat、其类似物、或其药学上可接受盐。
  3. 如权利要求2所述的组合物，其特征在于，所述组合物包括第一活性成分和第二活性成分，
    其中，所述第一活性成分为Quisinostat、其类似物、或其药学上可接受盐；
    所述第二活性成分为哌喹、其类似物、或其药学上可接受盐，和/或
    苯芴醇、其类似物、或其药学上可接受盐。
  4. 如权利要求2所述的组合物，其特征在于，所述疟原虫选自下组：恶性疟原虫、间日疟原虫、三日疟原虫和卵形疟原虫。
  5. 如权利要求3所述的组合物，其特征在于，所述哌喹为磷酸哌喹。
  6. 如权利要求2所述的组合物，其特征在于，所述组合物中还包括药学上可接受的载体或赋形剂。
  7. 如权利要求2所述的组合物，其特征在于，所述药物组合物的剂型包括片剂、颗粒剂、胶囊、丸剂、注射剂、或口服液。
  8. 如权利要求3所述的组合物，其特征在于，所述的组合物为单元剂型，每个单元剂型中所述第一活性成分和所述第二活性成分的含量约为日剂量的0.1至1(或0.25-1，或0.5-1)，其中所述日剂量为20-100mg。
  9. 如权利要求2所述的抗疟原虫组合物的用途，用于制备
    (1)预防和/或治疗疟疾的药物；
    (2)抑制和/或杀灭疟原虫的试剂。
  10. 一种预防和/或治疗疟疾的方法，其特征在于，所述方法包括步骤：
    给需要的对象施用Quisinostat、其类似物、或其药学上可接受盐，或者给需要的对象施用权利要求2所述的抗疟原虫组合物，从而预防和/或治疗疟疾。
PCT/CN2017/074255 2016-02-22 2017-02-21 Quisinostat，一种新型的高效抗疟药物 WO2017143964A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201610096388.9 2016-02-22
CN201610096388.9A CN107095871A (zh) 2016-02-22 2016-02-22 Quisinostat，一种新型的高效抗疟药物

Publications (1)

Publication Number Publication Date
WO2017143964A1 true WO2017143964A1 (zh) 2017-08-31

Family

ID=59658976

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2017/074255 WO2017143964A1 (zh) 2016-02-22 2017-02-21 Quisinostat，一种新型的高效抗疟药物

Country Status (2)

Country Link
CN (1) CN107095871A (zh)
WO (1) WO2017143964A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107929240A (zh) * 2017-12-13 2018-04-20 桂林南药股份有限公司 磷酸哌喹口服液及其制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1993353A (zh) * 2004-07-28 2007-07-04 詹森药业有限公司 作为组蛋白脱乙酰基酶新抑制剂的取代的吲哚基烷基氨基衍生物
CN101516374A (zh) * 2006-09-15 2009-08-26 詹森药业有限公司 具有针对i类和iib类组蛋白脱乙酰酶的组合活性的组蛋白脱乙酰酶抑制剂和蛋白酶体抑制剂的组合

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1993353A (zh) * 2004-07-28 2007-07-04 詹森药业有限公司 作为组蛋白脱乙酰基酶新抑制剂的取代的吲哚基烷基氨基衍生物
CN101516374A (zh) * 2006-09-15 2009-08-26 詹森药业有限公司 具有针对i类和iib类组蛋白脱乙酰酶的组合活性的组蛋白脱乙酰酶抑制剂和蛋白酶体抑制剂的组合

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GIANNINI, GIUSEPPE ET AL.: "Hydroxamic acid based histone deacetylase inhibitors with confirmed activity against the malaria parasite", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 25, no. 3, 19 December 2014 (2014-12-19), pages 459 - 461, XP029131262 *
GU, HUAWEI ET AL.: "Research progress of histone deacetylase inhibitors", CHINA MODERN MEDICINE, vol. 22, no. 16, 30 June 2015 (2015-06-30), pages 15 - 21 *
HAN, TAO ET AL.: "jian3shu4shi3yong4qing1hao1su41ian2he2xi1yao4zhi41iao2nve4ji2de1yan2jiu1jin4zhan3", CONTEMPORARY MEDICINE FORUM, vol. 13, no. 6, 31 December 2015 (2015-12-31), pages 10 - 11 *

Also Published As

Publication number Publication date
CN115487191A (zh) 2022-12-20
CN107095871A (zh) 2017-08-29

Similar Documents

Publication Publication Date Title
TWI387456B (zh) 用於治療瘧疾之二茂鐵氯奎（ｆｅｒｒｏｑｕｉｎｅ）及黃花蒿素（ａｒｔｅｍｉｓｉｎｉｎ）衍生物之組合
Warrell et al. Treatment and prevention of malaria
US8486987B2 (en) Mechanism-based small-molecule parasite inhibitors
Monzote et al. Activity, toxicity and analysis of resistance of essential oil from Chenopodium ambrosioides after intraperitoneal, oral and intralesional administration in BALB/c mice infected with Leishmania amazonensis: a preliminary study
US5219865A (en) Pharmaceutical combination for the prophylaxis and therapy of malaria
JP2002540156A (ja) 抗ウイルス治療用チアジアゾリルウレアまたはチオウレア誘導体
JPH02157223A (ja) 抗マラリア剤組成物
Shapiro et al. Chemotherapy of protozoal infections
WO2017143964A1 (zh) Quisinostat，一种新型的高效抗疟药物
JP2023512093A (ja) コロナウイルス感染の治療における４－アミノキノリン化合物の使用
SK283947B6 (sk) Farmaceutické kompozície tizoxanidu a nitazoxanidu
TW201000098A (en) Combination of a bisthiazolium salt or a precursor thereof and artemisinin or a derivative thereof for the treatment of severe malaria
CN115487191B (zh) Quisinostat，一种新型的高效抗疟药物
US11491162B2 (en) Combination of quinoline-4-carboxamides and benzonaphthyridine derivatives as antimalarial drug combination
EP2520297A1 (en) Rubreserine and its derivates with antiparasitic activity
EP2070522A1 (en) Compounds for preventing and treating plasmodium infections.
CN108883090A (zh) 用于寄生物的药物敏化的组合物和方法
Olalubi et al. In-vivo Evaluation of the antiplasmodial effect of Amodiaquine and Amodiaquine-Promethazine combination in Plasmodium berghei infected mice
JP5820812B2 (ja) マラリアの治療または予防におけるフェロキンの使用
KR102620231B1 (ko) 췌장암을 치료하기 위한 치료 조성물
JP2002540150A (ja) ウイルス治療
Blake Antimalarial exoerythrocytic stage drug discovery and resistance studies
WO2015001799A1 (ja) バベシア症の治療剤及び予防剤
Nandal et al. Recent advances, challenges and updates on the development of therapeutics for malaria
CN117281822A (zh) 一种含有阿托伐醌与伊维菌素的组合物及其途

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17755793

Country of ref document: EP

Kind code of ref document: A1

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205 DATED 05/12/2018)

122 Ep: pct application non-entry in european phase

Ref document number: 17755793

Country of ref document: EP

Kind code of ref document: A1